Landos Biopharma Announces Acceptance of Abstract on NX-13 Phase 1b Study in Ulcerative Colitis at 18th Annual Congress of the European Crohn’s and Colitis Organization
11 Enero 2023 - 6:00AM
Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”),
a clinical-stage biopharmaceutical company developing novel, oral
medicines for patients with autoimmune diseases, today announced
that an abstract on its Phase 1b Study to evaluate safety,
tolerability, pharmacokinetics and clinical efficacy of the
Nucleotide-binding oligomerization domain, Leucine rich Repeat
containing X1 (NLRX1) agonist NX-13 in Ulcerative Colitis (“UC”),
was accepted for poster presentation by the 18th Congress of the
European Crohn’s and Colitis Organization (“ECCO”).
“We are excited and appreciative that the ECCO Clinical Research
Committee has selected Landos’ NX-13 abstract for poster
presentation and look forward to continuing to advance this
potential new treatment through the clinic,” noted Dr. Fabio
Cataldi, Executive Vice-President & Chief Medical Officer at
Landos. “Our team is working hard to advance the upcoming NX-13
Phase 2 proof-of-concept clinical trial. And with a strong data
foundation, we are confident in our path forward and are excited
about the potential of NX-13 to potentially transform the current
treatment paradigm for moderate-to-severe UC patients.”
As previously announced, Landos is planning to conduct a Phase 2
proof-of-concept clinical trial for NX-13, which is expected to be
dose ranging, blinded, placebo-controlled, and statistically
powered. The Company is on track for first site activation and
patient enrollment for the NX-13 Phase 2 trial in the second
quarter of 2023, and expects to report topline data from the trial
by the fourth quarter of 2024.
“Improving the daily life of patients with IBD, including UC,
has always been my ultimate goal,” said Professor Laurent
Peyrin-Biroulet, President of ECCO and the lead author of the NX-13
abstract. “I believe potential new therapies like NX-13 will pave
the path for the future in managing autoimmune diseases.”
ECCO is the largest forum for specialists in Inflammatory Bowel
Disease (“IBD”) in the world. ECCO's mission is to improve the care
of patients with IBD in all its aspects through international
guidelines for practice, education, research, and
collaboration.
The NX-13 abstract will be featured as a poster presentation at
the annual ECCO Congress in Copenhagen from March 1 – March 4,
2023.
About Landos Biopharma Landos Biopharma is a
clinical stage biopharmaceutical company focused on the development
of first-in-class therapeutics for patients with autoimmune
disease. The Company’s mission is to create safer and more
effective treatments that address the therapeutic gap in the
current treatment paradigm.
Landos has a portfolio of three novel targets anchoring
libraries of immunometabolic modulation pathways, including seven
potentially first-in-class, once-daily therapies targeting 14
indications in the immunology space. This includes our three
clinical stage programs: NX-13 for Ulcerative Colitis and Crohn’s
Disease; Omilancor for Ulcerative Colitis, Crohn’s Disease and
Eosinophilic Esophagitis; and LABP-104 for Systemic Lupus
Erythematosus and Rheumatoid Arthritis
The Company is currently focused on advancing the clinical
development of NX-13 in Ulcerative Colitis.
For more information, please visit www.landosbiopharma.com.
Cautionary Note on Forward-Looking Statements
Statements in this press release about future expectations, plans
and prospects for Landos Biopharma, Inc. (the “Company”), including
statements about the Company’s strategy, clinical development and
regulatory plans for its product candidates and other statements
containing the words “anticipate”, “plan”, “expect”, “may”, “will”,
“could”, “believe”, “look forward”, “potential”, the negatives
thereof, variations thereon and similar expressions, or any
discussions of strategy constitute forward-looking statements.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including: the uncertainties inherent in the initiation
and enrollment of future clinical trials, including the planned
Phase 2 trial of NX-13, availability and timing of data from
ongoing clinical trials, expectations for regulatory approvals,
other matters that could affect the availability or commercial
potential of the Company’s product candidates and other similar
risks. Risks regarding the Company’s business are described in
detail in its Securities and Exchange Commission (“SEC”) filings,
including in its Annual Reports on Form 10-K and Quarterly Reports
on Form 10-Q, which are available on the SEC’s website at
www.sec.gov. Additional information will be made available in other
filings that the Company makes from time to time with the SEC. Such
risks may be amplified by the impacts of the COVID-19 pandemic. In
addition, the forward-looking statements included in this press
release represent the Company’s views only as of the date hereof.
The Company anticipates that subsequent events and developments
will cause the Company’s views to change. However, while the
Company may elect to update these forward-looking statements at
some point in the future, the Company specifically disclaims any
obligation to do so, except as may be required by law. These
forward-looking statements should not be relied upon as
representing the Company’s views as of any date subsequent to the
date hereof.
Investor ContactPatrick Truesdell, Principal
Accounting OfficerLandos Biopharmair@landosbiopharma.com
Media ContactTanner Kaufman / Kara SperryJoele
Frank, Wilkinson Brimmer Katcher212-355-4449
Landos Biopharma (NASDAQ:LABP)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
Landos Biopharma (NASDAQ:LABP)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024